Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Galecto
Biotech
Galecto buys leukemia drug, drops bone cancer asset in pivot
A year after the failure of a fibrosis drug sent Galecto on a search for salvation, the biotech has decided to go all-in on oncology and liver disease
James Waldron
Oct 7, 2024 10:07am
Galecto posts myelofibrosis data as search for savior continues
Dec 22, 2023 6:50am
Galecto lays off 70% in wake of fibrosis drug's phase 2 fail
Sep 27, 2023 7:50am
Galecto cans lung fibrosis med after ph. 2 fail, pivots to liver
Aug 15, 2023 7:30am
Galecto travels deeper into liver disease with GULLIVER-2 data
Nov 8, 2022 10:35am
Galecto links blood cancer prospect to reduced fibrosis
Sep 29, 2022 9:20am